Harrow (NASDAQ:HROW) Receives Buy Rating from B. Riley Financial

B. Riley Financial reaffirmed their buy rating on shares of Harrow (NASDAQ:HROW) in a research report released on Tuesday,Benzinga reports. They currently have a $65.00 price target on the stock, down from their prior price target of $74.00.

A number of other analysts have also weighed in on HROW. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald lowered their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. Finally, Nomura lowered shares of Harrow to a “neutral” rating in a research note on Wednesday, March 18th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Harrow has an average rating of “Moderate Buy” and a consensus price target of $69.86.

Harrow Stock Up 0.9%

NASDAQ HROW opened at $35.43 on Tuesday. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -208.40 and a beta of 0.31. Harrow has a 52 week low of $20.85 and a 52 week high of $54.85. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The company has a fifty day moving average of $41.75 and a two-hundred day moving average of $43.05.

Institutional Trading of Harrow

Hedge funds have recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Harrow during the fourth quarter valued at about $26,000. SBI Securities Co. Ltd. increased its holdings in shares of Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Harrow during the second quarter valued at about $48,000. State of Alaska Department of Revenue acquired a new position in shares of Harrow during the third quarter valued at about $83,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after acquiring an additional 369 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.